Table 2. Multivariate analysis of prognostic factors in the validation set with overall survival as an end point.
Variate | Hazard ratio | 95% confidence interval | P-value |
---|---|---|---|
Tumour size | |||
⩽5 cm | 1 | ||
>5 cm | 0.54 | 0.19–1.51 | 0.2400 |
Histological type | |||
Differentiated | 1 | ||
Undifferentiated | 1.97 | 0.78–4.97 | 0.1500 |
Serosal invasion | |||
Negative | 1 | ||
Positive | 3.38 | 1.21–9.50 | 0.0210 |
Lymph node metastasis | |||
Negative | 1 | ||
Positive | 0.78 | 0.37–1.65 | 0.5200 |
CEA mRNA status | |||
Negative | 1 | ||
Positive | 1.79 | 1.13–2.85 | 0.0130 |
CEA=carcinoembryonic antigen.